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Abstract: Imiquimod (IQ) is an immune-response modifying agent, ﬁ  rst approved by FDA for 
the topical treatment of external genital and perianal warts in 1997. It induces, through stimula-
tion of Toll-like receptors (TLRs) localized on the surface of antigen-presenting cells, synthesis 
and release of several endogenous pro-inﬂ  ammatory cytokines such as interferon-α (IFN-α), 
tumor necrosis factor-α (TNF-α) and interleukins (IL) 6 and 12, which in turn stimulate both 
the innate and acquired immune pathways, resulting in upregulation of natural antiviral and 
antitumor activity. IQ 5% cream has been used for the treatment of a wide variety of dermatologic 
conditions in which the immune system is thought to play a role in regression of the disease. 
In some disorders, such as genital and perianal warts, actinic keratoses, basal cell carcinomas, 
Bowen’s disease and molluscum contagiosum, relative safety and efﬁ  cacy are supported by 
randomized controlled trials of IQ. However, it is common for patients to experience local skin 
reactions, which can range from mild to severe in intensity, but usually resolve 1–2 weeks after 
interrupting treatment. Additional randomized trials are encouraged to assess safety and efﬁ  cacy 
of IQ in the treatment of an even wider range of cutaneous disorders.
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Introduction
Imiquimod (IQ) is a member of a class of immune-response modifying agents, ﬁ  rst approved 
by FDA for the topical treatment of external genital and perianal warts in 1997.
The effect of IQ cream on immunity has suggested its possible use in the treatment of 
a wide variety of dermatologic conditions in which the immune system is thought to play 
a role in regression of the disease (Tyring et al 2002; Vender and Goldberg 2005).
In this review recent literature regarding mechanism of action, clinical applications 
and safety of IQ will be discussed.
Mechanism of action
IQ (1-[2-methylpropyl]-1H-imidazo[4,5-c]quinolin-4-amine) is a synthetic imidazo-
quinoline amine that enhances, through cytokine induction, both the innate and acquired 
immune pathways, resulting in immunomodulating, antiviral and antitumor effects.
The mechanism of action of IQ is mainly related to the binding and stimulation of 
Toll-like receptors (TLRs), that are located on the surface of antigen-presenting cells, 
and serve to recognize and defend against invading pathogens (Chang et al 2005; Ceil-
ley and Del Rosso 2006; Patel et al 2006). IQ is a potent TLR-7 agonist which induces 
synthesis and release of several endogenous pro-inﬂ  ammatory cytokines from Lang-
erhans cells, monocytes/macrophages and dendritic cells. These include interferon-α 
(IFN-α), tumor necrosis factor-α (TNF-α) and interleukins (IL) 1, 6, 8, 10 and 12, 
which in turn activate and perpetuate cell-mediated immune responses primarily medi-
ated by lymphocytes CD4+ and CD8+ (Sauder 2003; Schiller et al 2006). In particular, 
IQ stimulates natural killer cells of the innate immune system and activates T helper 
cell type 1 and cytotoxic T lymphocytes responsible for killing virus-infected and Therapeutics and Clinical Risk Management 2008:4(1) 88
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tumor cells, as well as establishing immunological memory 
(Garland 2003).
Immune-system induction is believed to be responsible for 
both antiviral and antitumor activity of IQ. However, recent 
studies have demonstrated that IQ may directly stimulate pro-
duction of pro-apoptotic signalling. As a result, virus-infected 
keratinocytes and/or neoplastic cells are driven into apoptosis 
and eliminated. This process is mediated via death receptors, 
including Fas Receptor (FasR), a member of the tumor necrosis 
factor receptor family (Berman et al 2003). When FasR binds 
its ligand, namely Fas ligand (FasL), a cascade of events fol-
lows, including caspase activation, ultimately eventuating 
in cellular death. In a vehicle-controlled study, IQ induced 
expression of FasR in basal cell carcinoma (BCC) cells, lead-
ing to cell apoptosis. Normally, BCC cells fail to express FasR, 
thus preventing cell apoptosis via FasR-Fas ligand interaction 
(Berman et al 2003; Ceilley and Del Rosso 2006).
Clinical trials
IQ has been reported to be safe and effective in the treatment 
of a number of skin disorders (Table 1); however, the clinical 
literature is replete with case reports, limited case series and 
open label trials. This review will focus on those conditions 
in which IQ efﬁ  cacy is supported by at least one randomized 
controlled trial (RCT).
External genital and perianal warts
IQ 5% cream is FDA approved for the treatment of external 
genital and perianal warts. Its efﬁ  cacy in these disorders 
has been demonstrated in several RCTs (Beutner et al 1998; 
Edwards et al 1998; Perry and Lamb 1999; Garland et al 
2001; Sauder et al 2003; Scheinfeld and Lehman 2006).
In the largest RCT (Edwards et al 1998), 311 patients 
18 years of age and older with external genital/perianal warts 
were randomized to 3 arms (109:102:100) IQ 5% cream, 
IQ 1% cream or vehicle 3 times per week for a maximum 
of 16 weeks. Complete clearance (absence of lesions) was 
achieved in 50% of IQ 5% patients, 21% of IQ 1% patients 
and 11% of placebo patients. There was a signiﬁ  cantly better 
complete clearance response in female patients compared to 
males (72% vs 33% respectively) among the IQ 5% group. 
The mean time for complete clearance ranged from 8 weeks 
for women to 12 weeks for men. Recurrence rate of at least 1 
wart for patients treated with IQ 5% was 13% (12 weeks after 
treatment was stopped).
In an international open-label multicentre phase IIIB trial 
(Garland et al 2001) consisting of 943 patients from 114 clinic 
sites in 20 countries, IQ 5% cream was applied 3 times per 
week for up to 16 weeks with an overall complete clearance 
rate of nearly 48%. Recurrence rate at 6-months follow up was 
23%. This study also conﬁ  rmed a better clinical outcome in 
females (65%) compared to males (44%). The authors have 
hypothesized that the different outcome might be related 
to more incomplete keratinization of vulvar epithelium 
compared to that of male genitalia (Tyring et al 2002). The 
semi-occlusive effect of the foreskin has also played a role 
in the higher clearance rates observed among uncircumcised 
compared to circumcised individuals (Tyring et al 2002).
In another RCT (Beutner et al 1998) IQ 5% cream was 
applied once daily for up to 16 weeks. Complete wart clear-
ance occurred in 52% of patients, with 19% wart recurrence 
at a 12-week follow-up. These results are similar to those 
obtained with 3 applications/week (Edwards et al 1998; 
Garland et al 2001). Therefore, 3 times per week treatment 
schedule is recommended because of a relatively lower rate of 
side effects (Perry and Lamb 1999; Gupta et al 2004; Chang 
et al 2005; Scheinfeld and Lehman 2006).
Topical IQ appears to be less effective in immunosup-
pressed patients. In a RCT, 97 male HIV-positive patients 
with genital warts and receiving no antiretroviral therapy, 
were treated with either IQ or vehicle: the complete response 
rates were 11% and 6% respectively (Gilson et al 1999).
Although further trials are required to compare the efﬁ  cacy 
of IQ to other therapies, available data suggest that its efﬁ  cacy 
is similar to that of other treatment modalities, including 
intralesional interferon and podophyllotoxin, but with lower 
recurrence rates (Perry and Lamb 1999; Garland 2003).
Actinic keratoses
IQ 5% cream is also FDA-approved for the treatment of 
actinic keratoses (AKs) of face and scalp in immunocom-
petent individuals and its efﬁ  cacy has been demonstrated by 
several RCTs followed by three meta-analysis studies (Gupta 
et al 2005; Falagas et al 2006; Hadley et al 2006).
The ﬁ  rst meta-analysis study (Hadley et al 2006) included 
5 RCTs with a total of 1293 patients. Complete clearance 
occurred in 50% of patients treated with IQ 5% cream 
compared to 5% in the placebo group. The number needed 
to treat (representing the number of patients needed to be 
treated with IQ compared to vehicle to obtain one additional 
beneﬁ  cial event) was 2.2, showing that IQ 5% cream is an 
effective short term therapy.
Another meta-analysis study (Falagas et al 2006) iden-
tiﬁ  ed 4 RCTs including 1266 patients. In 2 studies IQ or 
vehicle cream was applied 3 times per week for 16 weeks, in 
one study applications were 3 times per week for 12 weeks, Therapeutics and Clinical Risk Management 2008:4(1) 89
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and in the fourth study, application rate was 2 times per week 
for 16 weeks. Meta-analysis for these studies showed com-
plete clearance of AKs ranging from 45 to 84% in patients 
treated with IQ compared to 0%–7% in the vehicle group 
(p   0.0001).
Most authors have observed that patients may experi-
ence an increase in the number of AKs within the treatment 
area at treatment initiation. This phenomenon is thought to 
be the result of the appearance of sub-clinical lesions rather 
than the formation of new ones (Falagas et al 2006). Thus 
IQ’s ability to uncover and treat sub-clinical lesions may be 
considered an additional beneﬁ  t of treatment with this drug 
(Falagas et al 2006). Moreover, clearance of AKs is more 
frequent in patients who developed intense erythema or 
other local reactions at the application site, suggesting that 
inﬂ  ammation is part of the mechanism of action for topical 
IQ (Falagas et al 2006).
A third meta-analysis study (Gupta et al 2005) of 10 clinical 
trials (4 RCTs with topical IQ and 6 RCTs with topical ﬂ  uo-
rouracil) indicated that IQ may have relatively higher efﬁ  cacy 
than topical ﬂ  uorouracil for AKs located on the face and scalp. 
The mean efﬁ  cacy rate for each drug (with 95% conﬁ  dence 
interval) was 5-ﬂ  uorouracil, 52 ± 18% (n = 6 studies, 145 sub-
jects) and IQ, 70 ± 12% (n = 4 studies, 393 subjects).
Long-term effectiveness of topical IQ in the treatment 
of AKs remains to be determined; only one RCT consisted 
of “long-term” follow-up (25 patients with 1-year follow-up 
had 10% recurrence rate) (Stockﬂ  eth et al 2002). Moreover, 
optimal frequency of application and duration of treatment 
need to be elucidated by further studies.
Basal cell carcinoma
Topical IQ 5% cream is FDA-approved for the treatment of 
small superﬁ  cial BCCs.
A Cochrane Skin Group analysis of 7 RCTs demonstrated IQ 
to be effective and well-tolerated in the treatment of both superﬁ  -
cial and nodular BCC (Figures 1 and 2), although response rates 
varied according to number of applications and BCC clinical 
type (superﬁ  cial vs nodular) (Bath-Hextal et al 2006).
A multicenter 6-week dose-response trial (Marks et al 
2001) on 99 patients with primary superﬁ  cial BCCs compar-
ing different application regimens of IQ 5% cream showed 
histological clearance rates of 100%, 88%, 73% and 70% for 
twice daily, once daily, 6 times weekly and 3 times weekly 
regimens, respectively. Another RCT of 128 patients (Geisse 
et al 2002) compared IQ in different dose regimens versus 
vehicle for superﬁ  cial BCCs ranging in size between 0.5 and 
2 cm2 for 12 weeks. Clearance rates were respectively 100%, 
Table 1 Topical imiquimod in the treatment of dermatologic disorders
Randomized clinical trials  Case reports
Genital and perianal warts  Extramammary Paget disease (Cohen et al 2006)
Actinic keratosis  Erythroplasia of Queyrat (Micali, Nasca et al 2003)
Basal cell carcinoma  Bowenoid papulosis (Goorney and Polorni 2004)
Bowen’s disease  Stucco keratosis (Stockﬂ  eth et al 2000)
Molluscum contagiosum  Porokeratosis of Mibelli (Jain 2006)
Leishmaniasis (plus antimonial agents) (Miranda-Verastegui et al 2005)  Invasive SSC (Martin-Garcia 2005)
  Verrucous carcinoma (Schalock et al 2006)
  Metastatic melanoma (Wolf et al 2003)
Non-randomized clinical trials  Cutaneous T-Cell lymphoma (Didona et al 2004)
Lentigo maligna (Naylor et al 2003)  Granuloma annulare (Badavanis et al 2005)
Vulvar intraepithelial neoplasia (Le et al 2006)  Infantile hemangioma (Hazen et al 2005)
Keloids (plus surgery) (Patel and Skinner 2006)  Genital herpes (Brummitt 2006)
  Elastosis perforans serpiginosa (Kelly and Purcell 2006)
  Pyogenic granuloma (Goldenberg et al 2006)
Case series  Langerhans cell hystiocytosis (Taverna et al 2006)
Morphea (Dytoc et al 2005)  Lymphomatoid papulosis (Hughes 2006)
Actinic cheilitis (Smith et al 2002)  Angiolymphoid hyperplasia (Redondo et al 2004)
Common warts (Micali, Dall’Oglio et al 2003)  Orf (Erbagci, Erbagci et al 2005)
Mycosis fungoides (Deeths et al 2005)  Hyalohyphomycosis (Erbagci, Tuncel et al 2005)
  Foreign body reaction (Baumann and Halem 2003)
  Trichilemmal carcinoma (Jo, Ko et al 2005)
  Eccrine poroma (Jo, Chin et al 2005)
  Lip papillomatosis (Rinne et al 2000)




Figure 1 Superﬁ  cial BCC of the scalp before (a) and after (b) 8 weeks of treatment with IQ 5% cream 5 applications/week: complete clearance.Therapeutics and Clinical Risk Management 2008:4(1) 91
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Figure 2 Nodular BCC of the nose before (a) and after (b) 6 weeks of treatment with IQ 5% cream 5 applications/week: complete clearance.
(a)
(b)Therapeutics and Clinical Risk Management 2008:4(1) 92
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87%, 81% and 52% for twice daily, once daily, 5 days per 
week and 3 days per week applications; clearance rate for 
vehicle was 19%.
A European multicenter study (Schulze et al 2005) of 
166 subjects evaluated the clinical efﬁ  cacy of IQ vs vehicle 
applied 7 times per weeks for 6 weeks: composite clear-
ance (based on both clinical and histological clearance) 
was demonstrated in 77% and 6% of cases respectively 
(p   0.001), while histological clearance occurred in 80% and 
6% of cases, respectively (p   0.001). However, in comparing 
5 vs 7 applications per week for 6 weeks (Geisse et al 2004), 
there was no statistically signiﬁ  cant or clinically meaningful 
difference in complete clearance rate between the 2 regimens 
(75% vs 73% composite clearance, based on both clinical and 
histological clearance). Therefore, the 5-times-per-week regi-
men is preferred, as it is able to provide a balance of efﬁ  cacy 
and safety, with fewer treatment-emergent side effects.
Nodular BCCs are more difﬁ  cult to treat with topical IQ, 
most likely because of the skin barrier effect and the deeper 
localization of tumor cells (Chang et al 2005). In a RCT of 
92 patients (Shumack et al 2002), the rates of subjects having 
no histological evidence of BCC in post-treatment excision 
specimens were 75%, 76%, 70% and 60% after 12 weeks for 
twice daily, once daily, ﬁ  ve days per week or three days per 
week respectively; treatment failure for vehicle was 87%. 
These results were conﬁ  rmed by a 6-week, randomized, open-
label, dose-response study evaluating 4 dosing regimens on 
99 patients, in which topical IQ application once daily for 
7 days per week resulted in the highest clearance rate (71%) 
(Shumack et al 2002).
Further, two studies comparing the use of topical IQ 
5% cream with and without occlusion in the treatment of 
superﬁ  cial and nodular BCCs (Sterry et al 2002) showed no 
signiﬁ  cant difference in early treatment failure for the two 
application modalities.
Finally, some case reports (no RCTs) have claimed posi-
tive responses to topical IQ 5% in large superﬁ  cial BCCs 
(Shumack et al 2004; Micali et al 2005) and multiple BCCs 
as observed in Gorlin syndrome (Kagy and Amonette 2000; 
Micali, Lacarrubba, et al 2003).
Indications for the use of topical IQ in the treatment of BCCs 
are summarized in Table 2. Further long-term studies on the efﬁ  -
cacy of topical IQ compared to surgery for BCCs are needed.
Bowen’s disease
A recent RCT has demonstrated the efﬁ  cacy of topical IQ 5% 
cream in the treatment of Bowen’s disease (Patel et al 2006). 
Thirty-one patients with biopsy-proven Bowen’s disease were 
randomly assigned to receive in a double-blind fashion either 
IQ 5% cream (Pt =15) or vehicle (Pt =16) daily for 16 weeks. 
At the end of the study, 9 of the 12 patients completing the 
study in the IQ group (75%) showed clinical and histological 
resolution, with no relapse during a 9-month follow-up period, 
while no improvement was recorded in the placebo group 
(p   0.001). The authors concluded that the lack of response 
in the 3 patients treated with IQ was associated with the pres-
ence of thick, hyperkeratotic lesions. The results from this 
single RCT are in agreement with several case reports and 
non-randomized clinical trials (Mackenzie-Wood et al 2001; 
Smith et al 2001), but further studies are required.
Molluscum contagiosum
The efﬁ  cacy of topical IQ 5% cream in childhood mollus-
cum contagiosum has been evaluated in a double-blind RCT 
(Theos et al 2004). Twenty-three children (age 1–9 years) 
were randomized to receive either IQ cream 5% (Pt = 12) 
or vehicle (Pt = 11) 3 times a week for 12 weeks. At the 
end of the study partial clinical clearance (  30% clear-
ance of lesions) was noted in 67% of IQ patients vs 18% 
of controls; also, complete clinical clearance was noted in 
33.3% vs 9.1% of patients, respectively. The mean percentage 
change in lesion count at week 12 was −46% in the IQ group 
and +27% in the vehicle group.
Further, two case series have reported some positive 
outcomes with topical IQ in treating molluscum contagiosum 
in both children and adults (Bayerl et al 2003; Hengge and 
Cusini 2003).
Safety
In all the RCTs examined in this review topical IQ 5% cream 
has demonstrated an acceptable safety proﬁ  le.
During treatment with topical IQ it is common for 
patients to experience local skin reactions that range from 
mild to severe, and may extend beyond the application site 
onto the surrounding skin. Such reactions include burning, 
pruritus, pain, tenderness, erythema, oedema, vesicles, 
erosions, ulcerations, excoriations, exudation and crust-
ing (Figures 3–4). In cases of acute reactions temporary 
Table 2 Topical imiquimod in the treatment of BCCs: indications
 •  Extensive, and/or multifocal, and/or multiple tumours
 •  Cosmetically sensitive anatomic sites (face)
 •  History of hypertrophic scarring and/or keloids
 •  Surgical risk factors (eg, age, associated disorders)
 •  Psychological condition of the patient
 •  Patient refusal to undergo surgical proceduresTherapeutics and Clinical Risk Management 2008:4(1) 93
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(a)
(b)
Figure 3 Local skin reactions during treatment with IQ 5% cream: marked erythema (a), erosion, exudation, and crusting (b).Therapeutics and Clinical Risk Management 2008:4(1) 94
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Figure 4 Local skin reactions during treatment with IQ 5% cream: crusting (a), marked erythema, erosion, and exudation (b).
(a)
(b)Therapeutics and Clinical Risk Management 2008:4(1) 95
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discontinuation (generally 1–2 weeks) and application of 
cold compresses is suggested. Superﬁ  cial scarring, pigmen-
tary changes, and, rarely, induction of other dermatoses 
(psoriasis, pemphigus foliaceus, aphthosis, vitiligo, angio-
edema, eruptive epidermoid cysts) have also been reported 
(Barton 2004; Gilliet et al 2004; Brown et al 2005; Marty et al 
2005; Mashiah and Brenner 2005; Zalaudek et al 2005).
Systemic absorption appears to be minimal and inﬂ  u-
enza-like or gastrointestinal symptoms (fatigue, fever and 
chills, arthralgias, myalgias, nausea, diarrhea) or induction 
of non-dermatologic disorders (chronic neuropathic pain, 
autoimmune spondyloarthropathy) are rare (Benson 2004; 
Chang et al 2005; Yi et al 2005).
Exposure to sunlight (including sunlamps) should be 
avoided or minimized during use of topical IQ because of 
concern for heightened sunburn susceptibility, therefore the 
use of sunscreen might be encouraged.
Safety of topical IQ during pregnancy is not established 
and thus its use is contraindicated. Animal studies did not 
show any evidence of teratogenicity or fetotoxicity. However, 
contraception is recommended for women of childbearing 
age using topical IQ (Scheinfeld and Lehman 2006).
Conclusions
IQ is a topically active immunomodulatory agent that is cur-
rently available as a 5% cream in single-use sachets for the 
treatment of some viral and non-viral conditions. It is gener-
ally applied sparingly at bedtime from 3 to 5 times per week 
and washed off in the morning (Chang et al 2005; Scheinfeld 
and Lehman 2006). For AKs and superﬁ  cial BCCs, it may be 
possible to reduce treatment cost by repeated use of a sachet, 
which is not advised when treating genital warts because of 
the potential risk of transferring infectious material into the 
sachet (Patel et al 2006).
The use of IQ in dermatologic disorders presents some 
advantages: the cream is self-applied by the patient, com-
pared to other therapeutic strategies, avoiding more costly 
and painful procedures (Perry and Lamb 1999; Bath-Hextal 
et al 2006); in addition, it provides a non-scarring cosmetic 
outcome, when compared to surgical procedures. Also, side 
effects are usually localized to the treatment site and resolve 
after treatment cessation.
Because of the potential properties of topical IQ, addi-
tional RCTs are encouraged to assess its efﬁ  cacy in the treat-
ment of other cutaneous disorders. Moreover, as the relatively 
reduced response rate in patients treated with topical IQ is 
apparently associated with fully keratinized skin, the use of 
adjuvant therapies to decrease the stratum corneum/epidermis 
barrier and improve drug penetration and efﬁ  cacy warrant 
further investigation (Patel et al 2006).
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